ABCC2 (2G9) Monoclonal Antibody

$IF(ICC) staining with ABCC2 (2G9) Monoclonal Antibody (bsm-54019R) at 1:100 in HepG2 cells (green). The nuclear counterstain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilized with 0.25% Triton X100\/PBS.$

IF(ICC) staining with ABCC2 (2G9) Monoclonal Antibody (bsm-54019R) at 1:100 in HepG2 cells (green). The nuclear counterstain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilized with 0.25% Triton X100\/PBS.

$IF(ICC) staining with ABCC2 (2G9) Monoclonal Antibody (bsm-54019R) at 1:100 in 293T cells (green). The nuclear counterstain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilized with 0.25% Triton X100\/PBS.$

IF(ICC) staining with ABCC2 (2G9) Monoclonal Antibody (bsm-54019R) at 1:100 in 293T cells (green). The nuclear counterstain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilized with 0.25% Triton X100\/PBS.

$Paraformaldehyde-fixed and paraffin-embedded Human Liver tissue incubated with ABCC2 (2G9) Monoclonal Antibody (bsm-54019R) at 1:100, overnight at 4\u00b0C, followed by a conjugated secondary antibody and DAB staining. Counter stained with hematoxylin$

Paraformaldehyde-fixed and paraffin-embedded Human Liver tissue incubated with ABCC2 (2G9) Monoclonal Antibody (bsm-54019R) at 1:100, overnight at 4\u00b0C, followed by a conjugated secondary antibody and DAB staining. Counter stained with hematoxylin

$Paraformaldehyde-fixed and paraffin-embedded Human Kidney tissue incubated with ABCC2 (2G9) Monoclonal Antibody (bsm-54019R) at 1:100, overnight at 4\u00b0C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.$

Paraformaldehyde-fixed and paraffin-embedded Human Kidney tissue incubated with ABCC2 (2G9) Monoclonal Antibody (bsm-54019R) at 1:100, overnight at 4\u00b0C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.

$Paraformaldehyde-fixed and paraffin-embedded Human Pancreas tissue incubated with ABCC2 (2G9) Monoclonal Antibody (bsm-54019R) at 1:100, overnight at 4\u00b0C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.$

Paraformaldehyde-fixed and paraffin-embedded Human Pancreas tissue incubated with ABCC2 (2G9) Monoclonal Antibody (bsm-54019R) at 1:100, overnight at 4\u00b0C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.

Flow cytometric analysis of A549 cells with ABCC2 (2G9) Monoclonal Antibody (bsm-54019R) at 1:100 dilution (red) compared with an unlabeled control (cells without incubation with primary antibody; black).

Applications

WB
FCM
IHC-P
IF(IHC-P)
IF(ICC)

Reactivity

Human

Overview
Catalog #	bsm-54019R
Product Name	ABCC2 (2G9) Monoclonal Antibody
Applications	WB, FCM, IHC-P, IF(IHC-P), IF(ICC)
Reactivity	Human
Specifications
Conjugation	Unconjugated
Host	Rabbit
Source	Human ABCC2 aa 800-1000
Clonality	Monoclonal
Clone #	#REF!
Isotype	IgG
Concentration	1ug/ul
Purification	Purified by Protein A.
Storage Buffer	0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
Storage Condition	Store at -20C for 12 months.
Target
Gene ID	1244
Swiss Prot	Q92887
Synonyms	Canalicular multispecific organic anion transporter 1, ATP-binding cassette sub-family C member 2, Canalicular multidrug resistance protein, Multidrug resistance-associated protein 2, ABCC2, CMOAT, CMOAT1, CMRP, MRP2
Background	Multi-drug resistance protein 2 (MRP2), also known as ABCC2, is an ATP binding cassette (ABC) transporter responsible for biliary excretion of xenobiotics, endobiotics, and their metabolites. Deficiency in ABCC2 results in the clinical disorder Dubin-Johnson syndrome. MRP2 is found to be expressed in a variety of human cancers, and is associated with resistance of tumor cells to various anticancer drugs including cisplatin. The predicted molecular weight of MRP2 is 174 kDa, while mature MRP2 usually has a slower migration around 190-250 kDa due to the glycosylation. Mediates hepatobiliary excretion of numerous organic anions. May function as a cellular cisplatin transporter.
Application Dilution
WB	1:300-5000
FCM	1:20-100
IHC-P	1:200-400
IF(IHC-P)	1:50-200
IF(ICC)	1:50-200